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Objectives: To assess the in vitro susceptibility of Actinobaculum schaalii to 12 antimicrobial agents as well as to
dissect the genetic basis of fluoroquinolone resistance.
Methods: Forty-eight human clinical isolates of A. schaalii collected in Switzerland and France were studied.
Each isolate was identified by 16S rRNA sequencing. MICs of amoxicillin, ceftriaxone, gentamicin, vancomycin,
clindamycin, linezolid, ciprofloxacin, levofloxacin, moxifloxacin, co-trimoxazole, nitrofurantoin and metronida-
zole were determined using the Etest method. Interpretation of results was made according to EUCAST clinical
breakpoints. The quinolone-resistance-determining regions (QRDRs) of gyrA and parC genes were also identified
and sequence analysis was performed for all 48 strains.
Results: All isolates were susceptible to amoxicillin, ceftriaxone, gentamicin, clindamycin (except three), vanco-
mycin, linezolid and nitrofurantoin, whereas 100% and 85% were resistant to ciprofloxacin/metronidazole
and co-trimoxazole, respectively. Greater than or equal to 90% of isolates were susceptible to the other
tested fluoroquinolones, and only one strain was highly resistant to levofloxacin (MIC ≥32 mg/L) and moxiflox-
acin (MIC 8 mg/L). All isolates that were susceptible or low-level resistant to levofloxacin/moxifloxacin (n¼47)
showed identical GyrA and ParC amino acid QRDR sequences. In contrast, the isolate exhibiting high-level resist-
ance to levofloxacin and moxifloxacin possessed a unique mutation in GyrA, Ala83Val (Escherichia coli number-
ing), whereas no mutation was present in ParC.
Conclusions: When an infection caused by A. schaalii is suspected, there is a risk of clinical failure by treating
with ciprofloxacin or co-trimoxazole, and b-lactams should be preferred. In addition, acquired resistance to
fluoroquinolones more active against Gram-positive bacteria is possible.
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Introduction
The genus Actinobaculum is closely related to the genera
Actinomyces, Arcanobacterium and Mobiluncus.1 These bacteria
are curved, non-motile, non-spore-forming Gram-positive bacilli
and they are catalase, oxidase and urease negative.1,2 They
grow preferentially at 378C under strictly anaerobic or micro-
aerophilic conditions.1 To date, four species have been described
(http://www.bacterio.cict.fr/): Actinobaculum schaalii (1997);
Actinobaculum suis (1997); Actinobaculum massiliae (2002);
and Actinobaculum urinale (2003). They are probably part of
the commensal flora of the human genital or urinary tract.1
Because of its slow growth and its similarity to normal bacterial
flora on skin and mucosa, A. schaalii is difficult to identify by
culture and is probably frequently considered as a contaminant.
However, A. schaalii has been reported to be responsible for
numerous urinary tract infections (UTIs), mainly in elderly
patients with underlying urological predispositions.2 – 4 Interest-
ingly, a recent study showed that 22% of 252 urine samples
from patients .60 years were positive for A. schaalii using
real-time PCR.3 This microorganism may also cause septic com-
plications such as urosepsis, abscess, osteomyelitis and endo-
carditis.2,4 – 6 Although A. schaalii is an emerging uropathogen,
in vitro susceptibility to antimicrobial agents has been poorly
evaluated, particularly in terms of MICs.
Resistance to quinolones is mainly related to the acquisition
of point mutations in DNA gyrase (GyrA) and topoisomerase
IV (ParC).7 Alterations predominantly occur in the so-called
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quinolone-resistance-determining region (QRDR). Note that
mutations appear most frequently at positions 83 and 87 in
GyrA and 80 and 84 in ParC (Escherichia coli numbering). Since
gyrA and parC sequences of A. schaalii are not available, the pres-
ence of specific variations in the QRDRs, which might explain
fluoroquinolone resistance, has not yet been documented.
The aim of this study was to determine the in vitro suscepti-
bility of 48 A. schaalii clinical isolates to 12 antimicrobial
agents including those commonly used for the treatment of
UTIs. The molecular analysis of fluoroquinolone resistance was
also attempted by determining the QRDR sequences of the
gyrA and parC genes.
Materials and methods
Bacterial isolates
We examined 48 clinical isolates of A. schaalii recovered from urine
(n¼28), blood (n¼11), abscess (n¼7), biopsy (n¼1) and urethral swab
(n¼1) samples including 10 collected between 2005 and 2008 from
Henri Mondor Hospital (Cre´teil, France), 28 collected between 2004 and
2010 from ADMED (La Chaux-de-Fonds, Switzerland),8 9 collected
between 2000 and 2010 from the University Hospital of Lausanne (Lau-
sanne, Switzerland) and 1 collected in 2010 from Dianalab (Geneva, Swit-
zerland). All 48 strains were accurately identified as A. schaalii by
sequencing of the 16S rRNA gene, as previously described.8
Antimicrobial susceptibility testing
MICs of the following 12 antibiotics were determined for all strains using
the Etest method (bioMe´rieux, Marcy l’E´toile, France): amoxicillin; ceftri-
axone; gentamicin; vancomycin; clindamycin; linezolid; ciprofloxacin;
levofloxacin; moxifloxacin; co-trimoxazole; nitrofurantoin; and metroni-
dazole. All tests were performed on freshly poured Schaedler agar sup-
plemented with 5 mg/mL haemin, 1 mg/mL vitamin K1 and 5% sheep
blood (lysed sheep blood for co-trimoxazole testing). The plates were
inoculated with a bacterial suspension adjusted to a turbidity equivalent
to that of a 1 McFarland standard in 0.9% NaCl and incubated anaerobi-
cally for 48 h. Bacteroides fragilis ATCC 25285 was used as a quality
control strain, and interpretation of results was made according to non-
related species EUCAST clinical breakpoints (www.eucast.org/), except for
co-trimoxazole (Enterobacteriaceae and Staphylococcus spp.), nitrofuran-
toin (E. coli and Staphylococcus saprophyticus responsible for uncompli-
cated UTIs) and clindamycin and metronidazole (Gram-positive
anaerobes).
PCR amplification and sequencing
Bacterial genomic DNA was extracted using the QIAmp DNA Mini Kit
(Qiagen, Courtaboeuf, France). The DNA fragments corresponding to
the QRDRs of gyrA and parC genes were first amplified using degenerate
primers as previously described.9 Based on these sequences, a novel pair
of specific primers for each gene was specifically designed for A. schaalii:
gyrA-As-F2 (5′-CGGAGACCGGCCAGATTC-3′) and gyrA-As-R2 (5′-GGTGAG
GATGGTCGGTTCC-3′) to give a 316 bp product for gyrA; and parC-As-F2
(5′-AGCGCCGTATTCTCTTCCAG-3′) and parC-As-R2 (5′-GTCCAGCGAAGAAAT
CATCG-3′) to give a 281 bp product for parC.
The PCR mixture (50 mL) contained 1× reaction buffer containing
1.5 mM MgCl2, 200 mM of each dNTP, 0.5 mM of each primer, 1.25 U of
Taq polymerase (Q-Biogene, Illkirch, France) and 150 ng of DNA tem-
plate. PCR amplifications were performed using an iCycler thermal
cycler (Bio-Rad, Marnes-la-Coquette, France) as follows: (i) an initial dena-
turation step of 5 min at 958C; (ii) 35 cycles of PCR, with one cycle
consisting of 30 s at 958C, 30 s at 558C and 30 s at 728C; and (iii) a
final extension step of 10 min at 728C. Purified PCR products were then
directly sequenced with the same sets of primers in both directions
(GATC Biotech, Konstanz, Germany). The nucleotide sequences were ana-
lysed using SeqScapeTM v2.0 software (Applied Biosystems, Courtaboeuf,
France). Multiple alignment and calculation of amino acid identity was
carried out using ClustalX software (version 1.83).
Nucleotide sequence accession numbers
The partial nucleotide sequences of gyrA and parC genes obtained from
the A. schaalii HM 883 strain were deposited in the GenBank database
under accession numbers HQ009514 and HQ009515, respectively.
Results
Antimicrobial susceptibility
According to EUCAST breakpoints, all isolates were susceptible to
amoxicillin, ceftriaxone, gentamicin, vancomycin, linezolid and
nitrofurantoin (Table 1). All isolates except three (MICs
≥256 mg/L) were highly susceptible to clindamycin (Table 1).
All isolates were resistant to ciprofloxacin, whereas 90% and
96% remained susceptible to levofloxacin and moxifloxacin,
respectively (Table 1). A single strain was highly resistant to levo-
floxacin (MIC ≥32 mg/L) and moxifloxacin (MIC 8 mg/L). Finally,
all isolates were resistant to metronidazole (MIC ≥256 mg/L),
whereas only 15% were susceptible to co-trimoxazole (Table 1).
QRDR sequences of gyrA and parC genes
The amino acid sequence of fragments corresponding to the QRDRs
of GyrA and ParC was compared with those from other bacterial
species (Figure 1). All isolates that were susceptible or low-level
resistant to levofloxacin/moxifloxacin (n¼47) showed sequences
identical to that of the A. schaalii HM 883 isolate (Figure 1). The
GyrA QRDR sequence ofA. schaaliipresented an amino acid identity
with other sequences ranging from 68% to 85%, with the highest
identity with Arcanobacterium haemolyticum (85%). The ParC
QRDR sequence of A. schaalii presented an amino acid identity
with the other sequences ranging from 50% to 88%, with again
the highest identity with A. haemolyticum (88%). More specifically,
they possessed an alanine (GyrA) or a threonine (ParC) at position
83/80 and an aspartate at position 87/84 (GyrA and ParC, according
to E. coli numbering) (Figure 1). In contrast, the single isolate
exhibiting high-level resistance to levofloxacin and moxifloxacin
possessed a unique mutation in GyrA (Ala83Val), whereas no
mutation was present in ParC.
Discussion
UTIs are predominantly caused by members of the family Enter-
obacteriaceae. However, Gram-positive bacteria and polymicro-
bial infections are not uncommon in patients with underlying
urological conditions. A. schaalii is an underestimated opportu-
nistic uropathogen and its search is relevant in cases of unex-
plained chronic pyuria, especially when there is discrepancy
between smear microscopy findings and growth results under
aerobic conditions.2,4
Although A. schaalii is an emerging uropathogen, particularly in
elderly patients, very little information is available about its in vitro
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susceptibility to antimicrobial agents, especially those commonly
used in the treatment of UTIs. To date, only one study determining
MIC50 and MIC90 values for nine strains has been conducted.
2
In the study by Reinhard et al.,2 all isolates were susceptible to
penicillin, cefuroxime, amoxicillin, nitrofurantoin, tetracycline
and clindamycin with MIC50s and MIC90s of 0.008 and
0.023 mg/L, ,0.016 and ,0.016 mg/L, 0.5 and 1 mg/L, 0.5 and
1 mg/L, 0.023 and 0.047 mg/L and 0.125 and 0.25 mg/L, respect-
ively, whereas reduced activities were seen with ciprofloxacin, with
MIC50 and MIC90 values of 1.5 and 2 mg/L.
2 In a Danish study
describing 76 strains of A. schaalii from 55 patients, all isolates
were resistant to trimethoprim and ciprofloxacin, whereas they
were susceptible to ampicillin and cefuroxime, and showed
varying susceptibility to sulphonamides, but MICs were not pro-
vided.4 In several clinical cases, antimicrobial susceptibility
testing has been performed using Etest or disc diffusion
methods only for a few antibiotics. An A. schaalii isolate respon-
sible for a vertebral osteomyelitis was susceptible to amoxicillin/
clavulanate (MIC 0.38 mg/L), ceftriaxone (MIC 0.125 mg/L), clin-
damycin (MIC 0.023 mg/L), rifampin (MIC ,0.002 mg/L), doxycy-
cline (MIC 0.125 mg/L) and vancomycin (MIC 0.25 mg/L).5 In
another clinical case, using the disc diffusion method, the
Table 1. In vitro activity of 12 antimicrobial agents against 48 clinical isolates of A. schaalii
Antimicrobial agent
MIC (mg/L)
Susceptibility breakpoint (mg/L)a Percentage susceptiblerange MIC50 MIC90
Amoxicillin 0.03–0.5 0.12 0.25 ≤2 100
Ceftriaxone ≤0.01–0.25 0.06 0.12 ≤1 100
Gentamicin 0.12–2 1 2 ≤2 100
Vancomycin 0.12–0.25 0.12 0.25 ≤2 100
Clindamycin ≤0.01 to ≥256 0.03 0.06 ≤4 94
Linezolid 0.12–1 0.5 1 ≤2 100
Ciprofloxacin 2 to ≥32 ≥32 ≥32 ≤0.5 0
Levofloxacin 0.5 to ≥32 1 2 ≤1 90
Moxifloxacin 0.25–8 0.5 0.5 ≤0.5 96
Co-trimoxazole 2 to ≥32 16 ≥32 ≤2 15
Nitrofurantoin 0.12–32 2 16 ≤64 100
Metronidazole ≥256 ≥256 ≥256 ≤4 0
aNon-related species EUCAST breakpoints were used for all antibiotics, except for co-trimoxazole (EUCAST breakpoints for Enterobacteriaceae and
Staphylococcus spp.), nitrofurantoin (EUCAST breakpoints for E. coli and S. saprophyticus responsible for uncomplicated UTIs) and clindamycin and
metronidazole (EUCAST breakpoints for Gram-positive anaerobes).
GyrA 
83  87 
A. schaalii      AKIVGDVMGHYHPHGDAAIYDTMVRLAQPWSMRYPLVSGQ
A. haemolyticum      VKIVGDVMGNFHPHGDAAIYDTMVRLVQPWNMRYPLVAGQ
A. odontolyticus      SRVVGEVMGNYHPHGDAAIYDALARLVQPWSLRYPLVAGQ
M. tuberculosis      ARSVAETMGNYHPHGDASIYDSLVRMAQPWSLRYPLVDGQ
P. acnes      SRVVGDVMGKYHPHGDSAIYDTLVRLAQPWAMRYKLVQGQ
S. pneumoniae      ARITGDVMGKYHPHGDSSIYEAMVRMAQWWSYRYMLVDGH
S. aureus      ARIVGDVMGKYHPHGDLSIYEAMVRMAQDFSYRYPLVDGQ
P. aeruginosa      ARVVGDVIGKYHPHGDTAVYDTIVRMAQPFSLRYMLVDGQ
E. coli      ARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLRYMLVDGQ
    : ..:.:*::***** ::*:::.*:.* :  ** ** *: 
ParC
80  84 
A. schaalii      SRVVGDVMGRLHPHGDTAIYDAMVRLAQPFTMRLPLVDGH
A. haemolyticum      SRVVGDVMGRLHPHGDAAIYDAMVRLAQDFSLRLPFVDGH
A. odontolyticus      QRVVGEVMGKLHPHGDSAIYEALVRLAQPFNLRVPLVDGH
P. acnes      ARVVGQVMGQLHPHGDAAIYDALVRTAQPWAMRLPLVDGH
S. pneumoniae      AKSVGNIMGNFHPHGDFSIYDAMVRMSQDWKNREILVEMH
S. aureus      AKTVGDVIGQYHPHGDSSVYEAMVRLSQDWKLRHVLIEMH
P. aeruginosa      ARTVGDVLGKFHPHGDSACYEAMVLMAQPFSYRYPLVDGQ
E. coli      ARTVGDVLGKYHPHGDSACYEAMVLMAQPFSYRYPLVDGQ
  : **:::*. ***** : *:*:*  :* :  *  ::: : 
Figure 1. Comparison of the amino acid sequences of GyrA and ParC QRDRs (amino acids 67–106 and 64–103, respectively, in E. coli numbering) of
A. schaalii and other bacterial species. Hot spot positions 83 and 87 in GyrA and 80 and 84 in ParC are highlighted in grey. Similarities in amino acid
sequences are marked by asterisks (same amino acid), colons (strong similarity) and dots (family similarity). Multiple sequence alignment was carried
out using ClustalX 1.83 software.
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isolate was susceptible to penicillin, amoxicillin, ceftriaxone, tetra-
cycline, clarithromycin, clindamycin, nitrofurantoin and
co-trimoxazole, whereas it was resistant to ciprofloxacin.10 Like
related species of Actinomyces, A. schaalii seems to be intrinsically
resistant to metronidazole, as expected for a facultative aerobic
species.11
The nature of the mutation (Ala83Val) in the QRDR of the gyrA
gene has already been demonstrated to be involved in the devel-
opment of quinolone resistance in Mycobacterium tuberculosis.12
Therefore, ParC did not seem to be the primary target of fluoro-
quinolones in A. schaalii, as opposed to other Gram-positive bac-
terial species, where mutations conferring quinolone resistance
occur preferentially in the parC gene.7 Interestingly, the strain
exhibiting high-level resistance to levofloxacin and moxifloxacin
was recovered from a patient who had received moxifloxacin
therapy for UTI before isolation of the resistant strain.
For patients with clinically documented UTIs who do not
respond to treatment with ciprofloxacin or co-trimoxazole, infec-
tion caused by A. schaalii should be suspected, and, if it is the
cause of the infection, treatment must be adjusted. Interest-
ingly, one case of chronic pyelonephritis due to A. schaalii has
been successfully treated after 6 weeks of clindamycin.13 Never-
theless, treatment with b-lactams has been successfully used in
several cases.2,5,6 However, the optimal duration of antimicrobial
drug treatment with b-lactams is not clearly defined even if
several weeks of treatment may be required in several cases.3
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